Patent application number | Description | Published |
20090042825 | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 02-12-2009 |
20090042829 | Nucleic Acid-Lipopolymer Compositions - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 02-12-2009 |
20100004313 | Modified Poloxamers for Gene Expression and Associated Methods - Nucleotide delivery polymers, compositions, and associated methods for the enhancement of gene delivery and expression in solid tissues are provided. In one aspect, for example, a nucleotide delivery polymer may include a poloxamer backbone having a metal chelator covalently coupled to at least one terminal end of the poloxamer backbone. In another aspect, the nucleotide expression polymer has a metal chelator coupled to at least two terminal ends of the poloxamer backbone. | 01-07-2010 |
20100004315 | Biodegradable Cross-Linked Branched Poly(Alkylene Imines) - Disclosed is a cross-linked branched poly(alkylenimine) and compositions thereof and nucleotide molecules. Also disclosed are methods for preparing the cross-linked branched poly(alkylenimine). | 01-07-2010 |
20100260817 | Polyamine Derivatives - Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules. | 10-14-2010 |
20120009145 | Biodegradable Cross-Linked Cationic Multi-block Copolymers for Gene Delivery and Methods of Making Thereof - A biodegradable cross-linked cationic multi-block copolymer of linear polyethylenimine (LPEI) wherein the LPEI blocks are linked together by hydrophilic linkers with a biodegradable disulfide bond and methods of making thereof. The biodegradable cross-linked cationic multi-block copolymer may also contain pendant functional moieties which are preferably receptor ligands, membrane permeating agents, endosomolytic agents, nuclear localization sequences, pH sensitive endosomolytic peptides, chromogenic or fluorescent dyes. | 01-12-2012 |
20130065942 | Nucleic Acid-Lipopolymer Compositions - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 03-14-2013 |
20130164845 | Compositions and Methods for the Delivery of Biologically Active RNAs - Novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds, vectors, cells, and compositions are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, discorders, or conditions in a subject or organism. | 06-27-2013 |
20130251809 | Polyamine Derivatives - Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules. | 09-26-2013 |
20140005254 | Compositions and methods for the Delivery of Biologically Active RNAs | 01-02-2014 |
20140050775 | Polyamine Derivatives - Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules. | 02-20-2014 |